Market overview
The global CRISPR and cas gene market is worth USD 2.9 bn in 2026 and is forecast to reach USD 10.1 bn by 2036, growing at a 13.5% CAGR. United States is the largest country market and Cas enzymes and kits is the largest by product segment.
| Scope | CRISPR and Cas genome-editing products for research and drug development: Cas enzymes and kits, guide RNAs and screening libraries, delivery reagents and contract editing and screening services, excluding approved therapies. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 2.5 bn |
| Value 2026 | USD 2.9 bn |
| Value 2036 | USD 10.1 bn |
| CAGR 2026-2036 | 13.5% |
| Volume 2026 | 1,311 thousand orders |
| Volume 2036 | 4,651 thousand orders |
| Average price 2026 | USD 2,174 per order |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
CRISPR and Cas Gene market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 2.9 bn |
| 2027 | USD 3.2 bn |
| 2028 | USD 3.7 bn |
| 2029 | USD 4.2 bn |
| 2030 | USD 4.7 bn |
| 2031 | USD 5.4 bn |
| 2032 | USD 6.1 bn |
| 2033 | USD 6.9 bn |
| 2034 | USD 7.8 bn |
| 2035 | USD 8.9 bn |
| 2036 | USD 10.1 bn |
CRISPR and Cas Gene market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cas enzymes and kits | 34.0% | 29.6% | USD 969 mn | 11.9% |
| Guide RNAs and libraries | 28.0% | 26.6% | USD 798 mn | 12.9% |
| Editing and screening services | 22.0% | 27.2% | USD 627 mn | 15.9% |
| Delivery reagents | 16.0% | 16.6% | USD 456 mn | 13.9% |
By end user
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmaceutical and biotechnology companies | 46.0% | 50.8% | USD 1.3 bn | 14.6% |
| Academic and research institutes | 38.0% | 30.8% | USD 1.1 bn | 11.1% |
| Contract research organisations | 16.0% | 18.4% | USD 456 mn | 15.1% |
By system type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cas9 nucleases | 56.0% | 50.0% | USD 1.6 bn | 12.2% |
| Cas12 systems | 18.0% | 20.0% | USD 513 mn | 14.7% |
| Base and prime editors | 14.0% | 20.0% | USD 399 mn | 17.6% |
| Other systems | 12.0% | 10.0% | USD 342 mn | 11.4% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Therapeutics | 44.0% | 50.0% | USD 1.3 bn | 15.0% |
| Research tools | 30.0% | 26.0% | USD 855 mn | 11.9% |
| Agricultural biotech | 14.0% | 14.0% | USD 399 mn | 13.5% |
| Diagnostics | 12.0% | 10.0% | USD 342 mn | 11.4% |
By delivery
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Viral vectors | 40.0% | 38.0% | USD 1.1 bn | 12.9% |
| Lipid nanoparticles | 30.0% | 34.0% | USD 855 mn | 14.9% |
| Electroporation | 20.0% | 17.0% | USD 570 mn | 11.7% |
| Other methods | 10.0% | 11.0% | USD 285 mn | 14.6% |
Top 25 countries for CRISPR and cas gene by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.0% of 2026 revenue and the 25 countries below together hold 97.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 1.2 bn | 42.0% | USD 4.2 bn | 13.3% |
| 2 | China | USD 428 mn | 15.0% | USD 1.8 bn | 15.3% |
| 3 | Germany | USD 171 mn | 6.0% | USD 546 mn | 12.3% |
| 4 | United Kingdom | USD 171 mn | 6.0% | USD 566 mn | 12.7% |
| 5 | Japan | USD 171 mn | 6.0% | USD 526 mn | 11.9% |
| 6 | South Korea | USD 86 mn | 3.0% | USD 324 mn | 14.2% |
| 7 | France | USD 86 mn | 3.0% | USD 273 mn | 12.3% |
| 8 | Canada | USD 86 mn | 3.0% | USD 283 mn | 12.7% |
| 9 | India | USD 71 mn | 2.5% | USD 324 mn | 16.3% |
| 10 | Switzerland | USD 71 mn | 2.5% | USD 233 mn | 12.6% |
| 11 | Netherlands | USD 44 mn | 1.6% | USD 153 mn | 13.2% |
| 12 | Australia | USD 40 mn | 1.4% | USD 136 mn | 13.2% |
| 13 | Belgium | USD 28 mn | 1.0% | USD 97 mn | 13.2% |
| 14 | Sweden | USD 25 mn | 0.9% | USD 87 mn | 13.1% |
| 15 | Singapore | USD 19 mn | 0.7% | USD 75 mn | 14.5% |
| 16 | Taiwan | USD 15 mn | 0.5% | USD 57 mn | 14.3% |
| 17 | Denmark | USD 12 mn | 0.4% | USD 42 mn | 13.2% |
| 18 | Israel | USD 10 mn | 0.4% | USD 35 mn | 13.2% |
| 19 | Spain | USD 8.6 mn | 0.3% | USD 29 mn | 13.1% |
| 20 | Italy | USD 7.1 mn | 0.2% | USD 24 mn | 13.0% |
| 21 | Brazil | USD 5.7 mn | 0.2% | USD 22 mn | 14.6% |
| 22 | Austria | USD 5.7 mn | 0.2% | USD 19 mn | 12.9% |
| 23 | Ireland | USD 4.3 mn | 0.1% | USD 15 mn | 13.5% |
| 24 | Poland | USD 4.0 mn | 0.1% | USD 15 mn | 14.3% |
| 25 | Mexico | USD 3.1 mn | 0.1% | USD 12 mn | 14.5% |
| Rest of world | USD 81 mn | 2.8% | USD 282 mn | 13.3% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Thermo Fisher Scientific
- Merck KGaA
- Danaher (IDT)
- Revvity
Group 2: Regional and specialist players
- GenScript
- Synthego
- Lonza
- Takara Bio
- New England Biolabs
- Agilent Technologies
- ToolGen
- Charles River Laboratories
Group 3: Emerging and niche players
- OriGene
- Cellecta
- Ubigene Biosciences
- Applied StemCell
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the CRISPR and cas gene market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 13.5% is calculated from the resulting values.
The market is divided by product, by end user, by system type, by application, by delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the CRISPR and cas gene market?
The global CRISPR and cas gene market is estimated at USD 2.5 bn in 2025 and USD 2.9 bn in 2026.
How fast will the CRISPR and cas gene market grow?
It is forecast to reach USD 10.1 bn by 2036, a compound annual growth rate of 13.5% from 2026, an increase of USD 7.3 bn.
Which country is the largest market for CRISPR and cas gene?
United States is the largest market by revenue at USD 1.2 bn in 2026, 42.0% of the global total. The three largest countries together hold 63.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 16.3% a year from 2026 to 2036.
Which CRISPR and cas gene segment is largest?
In the by product split, Cas enzymes and kits is the largest segment with 34.0% of 2026 revenue.
Who are the leading CRISPR and cas gene companies?
Global leaders include Thermo Fisher Scientific, Merck KGaA, Danaher (IDT), Revvity.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Gene SynthesisUSD 2.8 bn · 15.0% CAGR
- Laboratory Information Management SystemUSD 2.7 bn · 9.5% CAGR
- 3D Cell CultureUSD 2.7 bn · 12.0% CAGR
- Spray DryingUSD 3.0 bn · 5.3% CAGR
- Enzyme Linked Immunosorbent AssayUSD 3.1 bn · 5.2% CAGR
- Continuous Positive Airway Pressure (CPAP)USD 3.1 bn · 6.5% CAGR
- Chromatography ResinUSD 2.6 bn · 9.8% CAGR
- Lyophilization EquipmentUSD 3.1 bn · 7.6% CAGR
← Breast Cancer Grading Tools CRISPR-Integrated Gene Editing Delivery Devices →